With a promising MASH asset, muscle-sparing GLP-1 and new CEO, Rivus gets ready to make its mark
Rivus Pharmaceuticals’ CEO Jorge Bartolome said the biotech is on track to build a “truly differentiated” cardio metabolic portfolio.
Rivus Pharmaceuticals’ CEO Jorge Bartolome said the biotech is on track to build a “truly differentiated” cardio metabolic portfolio.